Glax­o­SmithK­line plumbs the dis­cov­ery field (again), bet­ting up to $815M for the lat­est add-on to its on­col­o­gy pipeline

Five years af­ter No­var­tis stepped up with a siz­able deal that gave them world­wide rights to Sur­face On­col­o­gy’s lead can­cer drug, Glax­o­SmithK­line is com­ing in at the oth­er end of the pipeline, snag­ging a pre­clin­i­cal nat­ur­al killer drug de­signed to whip up a more ef­fec­tive at­tack on can­cer cells.

Un­like a lot of the pre­clin­i­cal col­lab­o­ra­tions we’ve seen, GSK is al­so freight­ing this with a sig­nif­i­cant amount of cash: $85 mil­lion up­front plus $730 mil­lion in mile­stones. And they see this new ad­di­tion to the on­col­o­gy pipeline as a prime can­di­date for fu­ture com­bos — all the rage these days.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER